Cargando…

Comparison of the Efficacy of Rosuvastatin 5 mg and 10 mg in Patients of Type 2 Diabetes Mellitus With Dyslipidemia

Objectives We did this study intending to compare the efficacy of rosuvastatin 5 mg and 10 mg in patients of type 2 diabetes mellitus with dyslipidemia by validating their effect on lipid profile and the side effects. Methodology This study was carried out at the outpatient department of a tertiary...

Descripción completa

Detalles Bibliográficos
Autores principales: Aleem, Mudassar, Zainab, Alina, Hameed, Azfar, Khan, Abdul Basit, Ali, Syed Zahid, Younus, Shifa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958143/
https://www.ncbi.nlm.nih.gov/pubmed/35371720
http://dx.doi.org/10.7759/cureus.22595
_version_ 1784676888385421312
author Aleem, Mudassar
Zainab, Alina
Hameed, Azfar
Khan, Abdul Basit
Ali, Syed Zahid
Younus, Shifa
author_facet Aleem, Mudassar
Zainab, Alina
Hameed, Azfar
Khan, Abdul Basit
Ali, Syed Zahid
Younus, Shifa
author_sort Aleem, Mudassar
collection PubMed
description Objectives We did this study intending to compare the efficacy of rosuvastatin 5 mg and 10 mg in patients of type 2 diabetes mellitus with dyslipidemia by validating their effect on lipid profile and the side effects. Methodology This study was carried out at the outpatient department of a tertiary care hospital in Multan. Three hundred patients of both genders were included. The research approach employed a parallel-controlled, randomized study. After taking relevant history and physical examination, each patient’s fasting venous blood samples were taken and sent to the institutional laboratory to analyze glycated hemoglobin (HbA1c), baseline lipid levels for cholesterol, triglycerides, low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL), and high-density lipoprotein (HDL). Patients were divided into two groups based on the drug administered. One group was prescribed rosuvastatin 5 mg, and the other group was prescribed rosuvastatin 10 mg. Patients were followed up after six months to record the latest lipid profile. Data analysis was done through SPSS version 24. Results Patients in the two groups had similar lipid levels to start with. After six months of therapy, total serum cholesterol, triglycerides, and LDL-C were reduced to statistically significant levels in group two compared to group one. However, both groups showed a similar increase in serum levels of HDL-C. Patients treated with 10 mg rosuvastatin showed a slight decrease in BMI. Nine patients treated with 10 mg rosuvastatin reported myalgias compared to only one patient treated with a dose of 5 mg (p<0.005). Conclusion Our study concludes that both 5 mg and 10 mg of rosuvastatin exhibit the antihyperlipidemic effect, but high doses are associated with more side effects. Therefore, physicians should be aware of dose titration related to statins as it will ultimately lead to reduced cardiovascular mortality.
format Online
Article
Text
id pubmed-8958143
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-89581432022-03-31 Comparison of the Efficacy of Rosuvastatin 5 mg and 10 mg in Patients of Type 2 Diabetes Mellitus With Dyslipidemia Aleem, Mudassar Zainab, Alina Hameed, Azfar Khan, Abdul Basit Ali, Syed Zahid Younus, Shifa Cureus Cardiology Objectives We did this study intending to compare the efficacy of rosuvastatin 5 mg and 10 mg in patients of type 2 diabetes mellitus with dyslipidemia by validating their effect on lipid profile and the side effects. Methodology This study was carried out at the outpatient department of a tertiary care hospital in Multan. Three hundred patients of both genders were included. The research approach employed a parallel-controlled, randomized study. After taking relevant history and physical examination, each patient’s fasting venous blood samples were taken and sent to the institutional laboratory to analyze glycated hemoglobin (HbA1c), baseline lipid levels for cholesterol, triglycerides, low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL), and high-density lipoprotein (HDL). Patients were divided into two groups based on the drug administered. One group was prescribed rosuvastatin 5 mg, and the other group was prescribed rosuvastatin 10 mg. Patients were followed up after six months to record the latest lipid profile. Data analysis was done through SPSS version 24. Results Patients in the two groups had similar lipid levels to start with. After six months of therapy, total serum cholesterol, triglycerides, and LDL-C were reduced to statistically significant levels in group two compared to group one. However, both groups showed a similar increase in serum levels of HDL-C. Patients treated with 10 mg rosuvastatin showed a slight decrease in BMI. Nine patients treated with 10 mg rosuvastatin reported myalgias compared to only one patient treated with a dose of 5 mg (p<0.005). Conclusion Our study concludes that both 5 mg and 10 mg of rosuvastatin exhibit the antihyperlipidemic effect, but high doses are associated with more side effects. Therefore, physicians should be aware of dose titration related to statins as it will ultimately lead to reduced cardiovascular mortality. Cureus 2022-02-25 /pmc/articles/PMC8958143/ /pubmed/35371720 http://dx.doi.org/10.7759/cureus.22595 Text en Copyright © 2022, Aleem et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Cardiology
Aleem, Mudassar
Zainab, Alina
Hameed, Azfar
Khan, Abdul Basit
Ali, Syed Zahid
Younus, Shifa
Comparison of the Efficacy of Rosuvastatin 5 mg and 10 mg in Patients of Type 2 Diabetes Mellitus With Dyslipidemia
title Comparison of the Efficacy of Rosuvastatin 5 mg and 10 mg in Patients of Type 2 Diabetes Mellitus With Dyslipidemia
title_full Comparison of the Efficacy of Rosuvastatin 5 mg and 10 mg in Patients of Type 2 Diabetes Mellitus With Dyslipidemia
title_fullStr Comparison of the Efficacy of Rosuvastatin 5 mg and 10 mg in Patients of Type 2 Diabetes Mellitus With Dyslipidemia
title_full_unstemmed Comparison of the Efficacy of Rosuvastatin 5 mg and 10 mg in Patients of Type 2 Diabetes Mellitus With Dyslipidemia
title_short Comparison of the Efficacy of Rosuvastatin 5 mg and 10 mg in Patients of Type 2 Diabetes Mellitus With Dyslipidemia
title_sort comparison of the efficacy of rosuvastatin 5 mg and 10 mg in patients of type 2 diabetes mellitus with dyslipidemia
topic Cardiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958143/
https://www.ncbi.nlm.nih.gov/pubmed/35371720
http://dx.doi.org/10.7759/cureus.22595
work_keys_str_mv AT aleemmudassar comparisonoftheefficacyofrosuvastatin5mgand10mginpatientsoftype2diabetesmellituswithdyslipidemia
AT zainabalina comparisonoftheefficacyofrosuvastatin5mgand10mginpatientsoftype2diabetesmellituswithdyslipidemia
AT hameedazfar comparisonoftheefficacyofrosuvastatin5mgand10mginpatientsoftype2diabetesmellituswithdyslipidemia
AT khanabdulbasit comparisonoftheefficacyofrosuvastatin5mgand10mginpatientsoftype2diabetesmellituswithdyslipidemia
AT alisyedzahid comparisonoftheefficacyofrosuvastatin5mgand10mginpatientsoftype2diabetesmellituswithdyslipidemia
AT younusshifa comparisonoftheefficacyofrosuvastatin5mgand10mginpatientsoftype2diabetesmellituswithdyslipidemia